Compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are each independently --H or lower alkoxy; R.sub.3 and R.sub.4 are each independently lower alkyl; and R.sub.5 and R.sub.6 are each --OCH.sub.3, or together form --OCH.sub.2 O-- or --OCH.sub.2 CH.sub.2 O-- and pharmaceutically acceptable acid addition salts thereof are calcium channel blockers useful for treating cardiovascular disorders including angina, hypertension and congestive heart failure.

Tetrahydroisoquinoline amides having the general structure ##STR1## are disclosed, the substituents defined hereinbelow, which amides are useful in inhibiting human leukocyte and neutrophil elastaes.

Compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 and each independently --H or lower alkoxy; R.sub.3 and R.sub.4 are each independently lower alkyl; and R.sub.5 and R.sub.6 are each --OCH.sub.3, or together form --OCH.sub.2 O-- or --OCH.sub.2 CH.sub.2 O--, and pharmaceutically acceptable acid addition salts thereof are prepared by cyclizing, deoxygenating, coupling, or hydrogenating the intermediates disclosed herein.

The present invention relates to the use of tetrahydroisoquinoline derivatives of the general formula ##STR1## wherein A is aryl R.sup.1 is hydrogen, hydroxy, lower alkyl, lower alkoxy, R--CO-- or R--COO--, wherein R is lower alkyl; R.sup.2 is hydrogen, lower alkyl or cycloalkyl R.sup.3 -R.sup.7 are independently hydrogen, lower alkyl, lower alkoxy, hydroxy or R.sup.3 and R.sup.4 taken together are --(CH.sub.2).sub.n -- or R.sup.6 and R.sup.7 taken together are --OCH.sub.2 O-- and n is 3 or 4, a...

Novel 4-amino-6,7-dimethoxy-2-(6,7-disubstituted-1,2,3,4-tetrahydroisoquinol-2-y l)quinoline compounds have been prepared, including their pharmaceutically acceptable salts and various novel key intermediates therefor. These compounds are useful in therapy as anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Preferred compounds include 4-amino-6,7-dimethoxy-2-(6-hydroxy-7-methoxy-1,2,3,4-tetrahydroisoquinol-2 -yl)quinoline and 4-amino-6,7-dimetho...

A compound of the formula: ##STR1## wherein R.sup.1 is hydrogen or methyl, is prepared by condensing a compound of the formula: ##STR2## wherein R.sup.2 is alkyl, aryl or aralkyl and R.sup.1 is same as above, or a reactive derivative thereof with 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid or an ester thereof to give a compound of the formula: ##STR3## wherein R.sup.3 is an ester residue and R.sup.1 and R.sup.2 are same as above, followed by hydrolysis or ammonolysis of said compound (IV). ...

Tetrahydroisoquinoline compounds represented by the formula: ##SPC1## In which X is a hydroxy group, Y is a hydroxy group or Y taken with X is --O--CH.sub.2 --O--, Z is hydrogen or a hydroxy group, R.sub.1 is hydrogen or an alkyl group of one to four carbon atoms, R.sub.2 is hydrogen, an alkyl group of one to four carbon atoms or phenyl, pyrrolidinomethyl, piperidinomethyl, or morpholinomethyl, R.sub.3 and R.sub.4 each is an alkyl group of one to four carbon atoms or R.sub.3 taken with R.sub.4 a...

Tetrahydroisoquinoline 3-carboxamide derivatives of formula ##STR1## and pharmaceutically acceptable salts thereof wherein: X is (a) CH.sub.2 ; (b) S (c) O; or (d) C(CH.sub.3).sub.2 ; R.sub.1 and R.sub.2 are independently (a) hydrogen; (b) hydroxy; (c) alkyl; (d) alkoxy; (e) aralkoxy; or (f) halogen. Compounds of formula I inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore useful in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus...

Novel alkylenetris- and alkylenetetrakis-[1,2,3,4-tetrahydroisoquinoline] and -[3,4-dihydroisoquinoline] compounds, the pharmaceutically acceptable acid addition salts thereof and compositions containing such substances have been found useful for inhibiting the formation of blood clots in mammals and/or dissolving blood clots in mammals after they have been formed.

A compound, or a solvate or salt thereof, of formula (I): ##STR1## in which R represents a group of formula (II) ##STR2## in which R.sub.x is the remainder of a heterocyclic group, or an optionally substituted phenyl group; R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl or C.sub.4-12 cycloalkylalkyl groups, or together form a C.sub.2-8 branched or linear polymethylene or C.sub.2-6 alkenylene group, optionally substituted with a hetero-ato...